Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, January 7, 2013

Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients

ROCHESTER, N.Y.Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis.

VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the second clinical trial for this investigational drug.  Signaling cascades initiated by SEMA4D regulate activation and migration of inflammatory cells, inhibit remyelination, and disrupt endothelial tight junctions leading to breakdown of the blood-brain barrier.  

Each of these mechanisms is known to contribute to the severity and progression of neuroinflammatory/neurodegenerative diseases including multiple sclerosis.  Studies in multiple animal models have shown that anti-SEMA4D antibody can successfully ameliorate disease severity.

Dr. Maurice Zauderer , President and Chief Executive Officer of Vaccinex, said:  "It is particularly gratifying for Vaccinex to translate into the clinic the first therapeutic to target this important new class of regulatory molecules.  Research in our own and other laboratories has shown that the multiple activities of SEMA4D have a coordinated detrimental effect on progression of neurological diseases, several types of cancer, and some other inflammatory and/or degenerative conditions.  Vaccinex is currently completing a parallel trial of VX15/2503 antibody in patients with solid tumors and plans to continue to advance studies of the therapeutic benefit of this unique and novel agent."

About Vaccinex, Inc.
Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.  

Press Contact Raymond E. Watkins , Chief Operating Officer, Vaccinex, Inc.

SOURCE Vaccinex, Inc.

PR Newswire (


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit:  to register

No comments: